Thrombophlebitis Follow-up

  • Author: Melanie D Palm, MD, MBA, FAAD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jan 23, 2012
 

Further Outpatient Care

  • Follow up patients with SVT at weekly intervals until complete resolution occurs to ensure against its progression to DVT.
  • Routinely monitor patients with DVT, especially while they are receiving anticoagulant therapy.
Next

Deterrence/Prevention

  • The routine use of graduated support stockings (class I or II), especially when the patient is confined on an airplane or otherwise, is extremely important.
Previous
Next

Complications

  • The progression of SVT to DVT should be prevented.
  • DVT should be treated at the first sign of its development.
  • Untreated, DVT may result in life-threatening PE.
Previous
Next

Prognosis

  • See Mortality/Morbidity.
  • SVT and DVT both have an excellent prognosis if treated promptly. Proper treatment should result in rapid resolution.
  • After resolution of the acute problem, the following treatment options for the underlying varicose veins should be considered: ambulatory phlebectomy, ligation and stripping, endovenous radiofrequency ablation, and endovenous laser ablation.[114, 115, 116]
Previous
Next

Patient Education

Previous
 
Contributor Information and Disclosures
Author

Melanie D Palm, MD, MBA, FAAD  Altman Dermatology Associates

Melanie D Palm, MD, MBA, FAAD, is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Coauthor(s)

Zoltan Trizna, MD, PhD  Private Practice

Zoltan Trizna, MD, PhD is a member of the following medical societies: American Academy of Dermatology and Texas Medical Association

Disclosure: Nothing to disclose.

Mitchel P Goldman, MD  Voluntary Clinical Professor, Department of Internal Medicine, Division of Dermatology, University of California, San Diego Medical Center

Mitchel P Goldman, MD is a member of the following medical societies: Aerospace Medical Association, American Academy of Cosmetic Surgery, American Academy of Dermatology, American College of Phlebology, American Dermatological Association, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, American Society of Lipo-Suction Surgery, American Venous Forum, California Medical Association, Dermatology Foundation, International Society for Dermatologic Surgery, Noah Worcester Dermatological Society, Pacific Dermatologic Association, Phi Beta Kappa, San Diego County Medical Society, Society for Investigative Dermatology, and Women's Dermatologic Society

Disclosure: Lumenis Consulting fee Consulting; Syneron/Candela Grant/research funds Other; New Star Lasers Ownership interest Other; SkinMedica Grant/research funds Other

Specialty Editor Board

Carrie L Kovarik, MD  Assistant Professor of Dermatology, Dermatopathology, and Infectious Diseases, University of Pennsylvania School of Medicine

Carrie L Kovarik, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Julia R Nunley, MD  Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, and Women's Dermatologic Society

Disclosure: Nothing to disclose.

Glen H Crawford, MD  Assistant Clinical Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Chief, Division of Dermatology, The Pennsylvania Hospital

Glen H Crawford, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Phi Beta Kappa, and Society of USAF Flight Surgeons

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Saultz A, Mathews EL, Saultz JW, Judkins D. Clinical inquiries. Does hypercoagulopathy testing benefit patients with DVT?. J Fam Pract. May 2010;59(5):291-4. [Medline].

  2. Buchanan GS, Rodgers GM, Branch DW. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract Res Clin Obst Gynecol. 2003;138:128-34.

  3. Franchini M, Veneri D, Salvagno GL, Manzato F, Lippi G. Inherited thrombophilia. Clin Lab Sci. 2006;43:249-90.

  4. Whitlatch NL, Ortel TL. Thrombophilias: when should we test and how does it help. Semin Respir Crit Care Med. 2008;29:25-39.

  5. Thomas JH. Edgar J Poth lecture. Pathogenesis, diagnosis, and treatment of thrombosis. Am J Surg. Dec 1990;160(6):547-51. [Medline].

  6. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group?. Am J Surg. Oct 1970;120(4):527-30. [Medline].

  7. Samlaska CP, James WD. Superficial thrombophlebitis. II. Secondary hypercoagulable states. J Am Acad Dermatol. Jul 1990;23(1):1-18. [Medline].

  8. Schafer AI. The hypercoagulable states. Ann Intern Med. Jun 1985;102(6):814-28. [Medline].

  9. Chengelis DL, Bendick PJ, Glover JL, Brown OW, Ranval TJ. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg. Nov 1996;24(5):745-9. [Medline].

  10. Samama MM, Trossaert M, Horellou MH, Elalamy I, Conard J, Deschamps A. Risk of thrombosis in patients for factor V Leiden. Blood. 86;1995:4700-4702.

  11. Rick ME. Protein C and protein S. Vitamin K-dependent inhibitors of blood coagulation. JAMA. Feb 2 1990;263(5):701-3. [Medline].

  12. Bauer KA. Pathobiology of the hypercoagulable state: clinical features, laboratory evaluation, and management. In: Hoffman R, et al, eds. Hematology: Basic Principles and Clinical Practice. New York, NY: Churchill Livingstone; 1991.

  13. Friedman T, O'Brien Coon D, Michaels V J, Bontempo F, Young VL, Clavijo JA, et al. Hereditary coagulopathies: practical diagnosis and management for the plastic surgeon. Plast Reconstr Surg. May 2010;125(5):1544-52. [Medline].

  14. Collen D, Schetz J, de Cock F, Holmer E, Verstraete M. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest. Feb 1977;7(1):27-35. [Medline].

  15. Odegård OR, Abildgaard U. Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis. 1978;7(2-3):127-34. [Medline].

  16. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. Aug 1999;82(2):610-9. [Medline].

  17. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. Oct 15 1987;317(16):991-6. [Medline].

  18. Engesser L, Broekmans AW, Briët E, Brommer EJ, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med. May 1987;106(5):677-82. [Medline].

  19. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. Feb 24 1994;330(8):517-22. [Medline].

  20. Peus D, Heit JA, Pittelkow MR. Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?. J Am Acad Dermatol. Apr 1997;36(4):616-20. [Medline].

  21. Nichols WL, Heit JA. Activated protein C resistance and thrombosis. Mayo Clin Proc. Sep 1996;71(9):897-8. [Medline].

  22. Towne JB. Hypercoagulable states and unexplained vascular graft thrombosis. In: Bernhard VM, Towne JB, eds. Complications in Vascular Surgery. St. Louis, Mo: Quality Medical Publishing; 1991.

  23. Espinoza LR, Hartmann RC. Significance of the lupus anticoagulant. Am J Hematol. Jul 1986;22(3):331-7. [Medline].

  24. Tabachnik-Schor NF, Lipton SA. Association of lupuslike anticoagulant and nonvasculitic cerebral infarction. Arch Neurol. Aug 1986;43(8):851-2. [Medline].

  25. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med. Jun 1990;20(3):231-6. [Medline].

  26. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. Feb 1980;92(2 Pt 1):156-9. [Medline].

  27. Elias M, Eldor A. Thromboembolism in patients with the 'lupus'-type circulating anticoagulant. Arch Intern Med. Mar 1984;144(3):510-5. [Medline].

  28. Kaplan NM. Cardiovascular complications of oral contraceptives. Annu Rev Med. 1978;29:31-40. [Medline].

  29. Durand JL, Bressler R. Clinical pharmacology of the steroidal oral contraceptives. Adv Intern Med. 1979;24:97-126. [Medline].

  30. Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol. Sep 1975;102(3):197-208. [Medline].

  31. DeSancho MT, Dorff T, Rand JH. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagul Fibrinolysis. Sep 2010;21(6):534-8. [Medline].

  32. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed). Feb 22 1986;292(6519):526. [Medline].

  33. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol. Jan 1987;69(1):91-5. [Medline].

  34. Robinson GE, Burren T, Mackie IJ, Bounds W, Walshe K, Faint R, et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ. Feb 2 1991;302(6771):269-71. [Medline].

  35. Seigel DG. Pregnancy, the puerperium and the steroid contraceptive. Milbank Mem Fund Q. Jan 1972;50(1):Suppl 2:15-23. [Medline].

  36. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Report from the Boston Collaborative Drug Surveillance Programme. Lancet. Jun 23 1973;1(7817):1399-404. [Medline].

  37. Quinn DA, Thompson BT, Terrin ML, Thrall JH, Athanasoulis CA, McKusick KA, et al. A prospective investigation of pulmonary embolism in women and men. JAMA. Oct 7 1992;268(13):1689-96. [Medline].

  38. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. Nov 1 1982;144(5):511-8. [Medline].

  39. Grady D, Hulley SB, Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA. Aug 13 1997;278(6):477. [Medline].

  40. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med. Sep 10 1981;305(11):612-8. [Medline].

  41. Alkjaersig N, Fletcher A, Burstein R. Association between oral contraceptive use and thromboembolism: a new approach to itsinvestigation based on plasma fibrinogen chromatography. Am J Obstet Gynecol. May 1975;122(2):199-211. [Medline].

  42. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost. Dec 22 1988;60(3):361-4. [Medline].

  43. Srinivasan S, Solash J, Redner A, Moser C, Farhangian D, Lucas TR, et al. The alteration of surface charge characteristics of the vascular system by oral contraceptive steroids. Contraception. Mar 1974;9(3):291-303. [Medline].

  44. Oski FA, Lubin B, Buchert ED. Reduced red cell filterability with oral contraceptive agents. Ann Intern Med. Sep 1972;77(3):417-9. [Medline].

  45. Aronson HB, Magora F, Schenker JG. Effect of oral contraceptives on blood viscosity. Am J Obstet Gynecol. Aug 1 1971;110(7):997-1001. [Medline].

  46. Dreyer NA, Pizzo SV. Blood coagulation and idiopathic thromboembolism among fertile women. Contraception. Aug 1980;22(2):123-35. [Medline].

  47. Sagar S, Stamatakis JD, Thomas DP, Kakkar VV. Oral contraceptives, antithrombin- III activity, and postoperative deep-vein thrombosis. Lancet. Mar 6 1976;1(7958):509-11. [Medline].

  48. von Kaulla E, von Kaulla KN. Oral contraceptives and low antithrombin-3 activity. Lancet. Jan 3 1970;1(7636):36. [Medline].

  49. Pizzo SV. Venous thrombosis. In: Koepke JA, ed. Laboratory Hematology. Vol 2. New York, NY: Churchill Livingstone; 1984.

  50. Miller KE, Pizzo SV. Venous and arterial thromboembolic disease in women using oral contraceptives. Am J Obstet Gynecol. Dec 1 1982;144(7):824-7. [Medline].

  51. Astedt B, Isacson S, Nilsson IM, Pandolfi M. Thrombosis and oral contraceptives: possible predisposition. Br Med J. Dec 15 1973;4(5893):631-4. [Medline].

  52. Judd HL, Meldrum DR, Deftos LJ, Henderson BE. Estrogen replacement therapy: indications and complications. Ann Intern Med. Feb 1983;98(2):195-205. [Medline].

  53. Goodrich SM, Wood JE. The effect of estradiol-17-beta on peripheral venous distensibility and velocity of venous blood flow. Am J Obstet Gynecol. Oct 1 1966;96(3):407-12. [Medline].

  54. Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med. Feb 1988;111(2):224-8. [Medline].

  55. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. Jun 1984;68(6):887-9. [Medline].

  56. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. Feb 23 1989;320(8):479-84. [Medline].

  57. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res. Aug 15 1987;47(16):4517-9. [Medline].

  58. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med. Feb 1992;152(2):317-20. [Medline].

  59. Auger MJ, Mackie MJ. Effects of tamoxifen on blood coagulation. Cancer. Apr 1 1988;61(7):1316-9. [Medline].

  60. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. Dec 1988;12(3):307-10. [Medline].

  61. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. May 15 1997;79(10):2024-7. [Medline].

  62. Bonnar J. Hemostatic function and coagulopathy during pregnancy. Obstet Gynecol Annu. 1978;7:195-217. [Medline].

  63. Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J. Aug 16 1969;3(5667):387-9. [Medline].

  64. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood. Oct 1986;68(4):881-5. [Medline].

  65. Aaro LA, Johnson TR, Juergens JL. Acute deep venous thrombosis associated with pregnancy. Obstet Gynecol. Oct 1966;28(4):553-8. [Medline].

  66. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJM. Pregnancy, the postpartum period and postthrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6:632-637.

  67. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. Oct 1997;78(4):1183-8. [Medline].

  68. Beller FK. Thromboembolic disease in pregnancy. In: Anderson A, ed. Thromboembolic Disorders. New York, NY: Harper & Row; 1968.

  69. Homans J. Thrombosis of the deep leg veins due to prolonged sitting. N Engl J Med. Jan 28 1954;250(4):148-9. [Medline].

  70. Lord RS, McGrath M. Travelers venous thrombosis. Presented at: The International Society of Cardiovascular Surgery Meeting. Lisbon, Portugal: 1993.

  71. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. Apr 2007;44(2):62-9. [Medline].

  72. Lord RS. Air travel-related deep venous thrombosis. Sydney views. Cardiovasc Surg. Apr 2001;9(2):149-50; discussion 153-6. [Medline].

  73. Parsi KA, McGrath MA, Lord RS. Traveller's venous thromboembolism. Cardiovasc Surg. Apr 2001;9(2):157-8. [Medline].

  74. McQuillan AD, Eikelboom JW, Baker RI. Venous thromboembolism in travellers: can we identify those at risk?. Blood Coagul Fibrinolysis. Oct 2003;14(7):671-5. [Medline].

  75. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110:1723-1729.

  76. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther. Nov 2007;29(11):2395-405. [Medline].

  77. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. Dec 15 1994;331(24):1601-6. [Medline].

  78. Perry SL, Ortel TL. Clinical and laboratory evaluation of thrombophilia. Clin Chest Med. Mar 2003;24(1):153-70. [Medline].

  79. Kowalewski R, Sobolewski K, Wolanska M, Gacko M. Matrix metalloproteinases in the vein wall. Int Angiol. Jun 2004;23(2):164-9. [Medline].

  80. Kagel EM, Rayan GM. Intravenous catheter complications in the hand and forearm. J Trauma. Jan 2004;56(1):123-7. [Medline].

  81. Gupta A, Mehta Y, Juneja R, Trehan N. The effect of cannula material on the incidence of peripheral venous thrombophlebitis. Anaesthesia. Nov 2007;62(11):1139-42. [Medline].

  82. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. Dec 1 2003;68(11):2189-96. [Medline].

  83. Hochmair M, Valipour A, Oschatz E, Hollaus P, Huber M, Chris Burghuber O. From a sore throat to the intensive care unit: the Lemierre syndrome. Wien Klin Wochenschr. May 2006;118(7-8):243-6. [Medline].

  84. Brinsuk M, Tank J, Luft FC, Busjahn A, Jordan J. Heritability of venous function in humans. Arterioscler Thromb Vasc Biol. Jan 2004;24(1):207-11. [Medline].

  85. Belcaro G, Nicolaides AN, Errichi BM, Cesarone MR, De Sanctis MT, Incandela L, et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. Angiology. Jul 1999;50(7):523-9. [Medline].

  86. Agnelli G, Verso M, Ageno W, Imberti D, Moia M, Palareti G, et al. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Research. 2008;121:605-610.

  87. Plate G, Eklöf B, Jensen R, Ohlin P. Deep venous thrombosis, pulmonary embolism and acute surgery in thrombophlebitis of the long saphenous vein. Acta Chir Scand. 1985;151(3):241-4. [Medline].

  88. Gjores JE. Surgical therapy of ascending thrombophlebitis in the saphenous system. Angiology. May 1962;13:241-3. [Medline].

  89. Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg. Feb 1985;72(2):105-8. [Medline].

  90. Bergqvist D, Jaroszewski H. Deep vein thrombosis in patients with superficial thrombophlebitis of the leg. Br Med J (Clin Res Ed). Mar 8 1986;292(6521):658-9. [Medline].

  91. Galloway JM, Karmody AM, Mavor GE. Thrombophlebitis of the long saphenous vein complicated by pulmonary embolism. Br J Surg. May 1969;56(5):360-1. [Medline].

  92. Leon L, Giannoukas AD, Dodd D, Chan P, Labropoulos N. Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg. Jan 2005;29(1):10-7. [Medline].

  93. Schönauer V, Kyrle PA, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Superficial thrombophlebitis and risk for recurrent venous thromboembolism. J Vasc Surg. Apr 2003;37(4):834-8. [Medline].

  94. Bendick PJ, Ryan R, Alpers M, et al. Clinical significance of superficial thrombophlebitis. J Vasc Technol. 1995;19:57-61.

  95. Verlato F, Zucchetta P, Prandoni P, Camporese G, Marzola MC, Salmistraro G, et al. An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg. Dec 1999;30(6):1113-5. [Medline].

  96. Krunes U, Lindner F, Lindner R, Gnutzmann J. Genugt die klinische untersuchung einer varikophlebitis des unterschenkels?. Phlebologie. 1999;28:93-6.

  97. Trujillo-Santos J, Herrera S, Rpage MA, Soto MJ, Raventós A, Sánchez R, et al. Predicting adverse outcome in outpatients with acute deep vein thrombosis: findings from the RIETE Registry. J Vasc Surg. 2006;44:789-793.

  98. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Trends Hematol Oncol. 2002;87:1095-1108.

  99. Crandon AJ, Peel KR, Anderson JA, Thompson V, McNicol GP. Postoperative deep vein thrombosis: identifying high-risk patients. Br Med J. Aug 2 1980;281(6236):343-4. [Medline].

  100. Sue-Ling HM, Johnston D, McMahon MJ, Philips PR, Davies JA. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. Lancet. May 24 1986;1(8491):1173-6. [Medline].

  101. Coon WW. Epidemiology of venous thromboembolism. Ann Surg. Aug 1977;186(2):149-64. [Medline].

  102. Schina MJ Jr, Neumyer MM, Healy DA, Atnip RG, Thiele BL. Influence of age on venous physiologic parameters. J Vasc Surg. Nov 1993;18(5):749-52. [Medline].

  103. Greenleaf JE, Rehrer NJ, Mohler SR, Quach DT, Evans DG. Airline chair-rest deconditioning: induction of immobilisation thromboemboli?. Sports Med. 2004;34(11):705-25. [Medline].

  104. Nachmann MM, Jaffe JS, Ginsberg PC, Horrow MM, Harkaway RC. Sickle cell episode manifesting as superficial thrombophlebitis of the penis. J Am Osteopath Assoc. Feb 2003;103(2):102-4. [Medline].

  105. Di Nisio M,Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database of Systematic Reviews. 2007;2:1-90.

  106. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ, Wakefield TW. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg. Nov 1998;28(5):848-54. [Medline].

  107. Marchiori A, Verlato F, Sabbion P, Camporese G, Rosso F, Mosena L, et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica. May 2002;87(5):523-7. [Medline].

  108. Sacher R. Antithrombin deficiency in special clinical syndromes--Part II: panel discussion #2. Semin Hematol. Oct 1995;32(4 Suppl 2):67-71. [Medline].

  109. Chengelis DL, Bendick PJ, Glover JL, Brown OW, Ranval TJ. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg. Nov 1996;24(5):745-9. [Medline].

  110. Sigg K. The treatment of varicosities and accompanying complications; (the ambulatory treatment of phlebitis with compression bandage). Angiology. Oct 1952;3(5):355-79. [Medline].

  111. Belcaro G, Cesarone MR, Rohdewald P, Ricci A, Ippolito E, Dugall M, et al. Prevention of venous thrombosis and thrombophlebitis in long-haul flights with pycnogenol. Clin Appl Thromb Hemost. Oct 2004;10(4):373-7. [Medline].

  112. De Sanctis MT, Cesarone MR, Incandela L, Belcaro G, Griffin M. Treatment of superficial vein thrombophlebitis of the arm with Essaven gel--a placebo-controlled, randomized study. Angiology. Dec 2001;52 Suppl 3:S63-7. [Medline].

  113. Beatty J, Fitridge R, Benveniste G, Greenstein D. Acute superficial venous thrombophlebitis: does emergency surgery have a role?. Int Angiol. Mar 2002;21(1):93-5. [Medline].

  114. Belcaro G, Nicolaides AN, Errichi BM, Cesarone MR, De Sanctis MT, Incandela L. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. Angiology. Jul 1999;50(7):523-9. [Medline].

  115. Ascer E, Lorensen E, Pollina RM, Gennaro M. Preliminary results of a nonoperative approach to saphenofemoral junction thrombophlebitis. J Vasc Surg. Nov 1995;22(5):616-21. [Medline].

  116. Campbell B. Varicose veins and their management. BMJ. Aug 5 2006;333(7562):287-92. [Medline].

  117. Torpy JM, Burke AE, Glass RM. JAMA patient page. Thrombophlebitis. JAMA. Jul 26 2006;296(4):468. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.